Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1036 to 1050 of 1308 results for social care

  1. Public board meeting agenda and papers: July 2022

    Agenda and papers of the NICE public board meeting on 22 July

  2. Mirabegron for treating symptoms of overactive bladder (TA290)

    Evidence-based recommendations on mirabegron (Betmiga) for treating overactive bladder in adults.

    Technology appraisal guidance
    Published
    26 June 2013
    View recommendations

    Sections for TA290

  3. Structured clinical management interventions in probation service providers:- What is the effectiveness of structured clinical (case) management in improving mental health outcomes using interventions within probation service providers?

    both CRCs and the NPS. The comparison should be against standard CRC and NPS care. The trial should consider both clinical outcomes and...

    Research recommendation
    Published
    16 May 2017

  4. FLEXISEQ for osteoarthritis (MIB80)

    NICE has developed a medtech innovation briefing (MIB) on FLEXISEQ for osteoarthritis

    Medtech innovation briefing
    Published
    14 September 2016

  5. TNF-alpha inhibitors for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)

    Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with active ankylosing spondylitis or non-radiographic axial spondyloarthritis .

    Technology appraisal guidance
    Published
    1 February 2016
    View recommendations

    Sections for TA383

  6. Biomarker tests to help diagnose preterm labour in women with intact membranes (HTG476)

    Evidence-based recommendations on biomarker tests to help diagnose preterm labour in women with intact membranes. The tests are Actim Partus, PartoSure and the Rapid fetal fibronectin (fFN) 10Q Cassette Kit (at thresholds other than 50 nanograms/millilitre).

    HealthTech guidance
    Published
    4 July 2018
    View recommendations

    Sections for HTG476

  7. Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]

    In development Reference number: GID-TA10555 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Pacritinib for treating myelofibrosis [ID880]

    Discontinued Reference number: GID-TA10133

    Technology appraisal guidance
    Discontinued

  9. Human growth hormone (somatropin) for the treatment of growth failure in children (TA188)

    Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humatrope, Norditropin, NutropinAq, Omnitrope, Saizen, Zomacton) for treating growth failure in children.

    Technology appraisal guidance
    Published
    26 May 2010
    View recommendations

    Sections for TA188

  10. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (HTG719)

    Evidence-based recommendations on tumour profiling tests (EndoPredict, ICH4+C, MammaPrint, Oncotype DX and Prosigna) to guide adjuvant chemotherapy decisions in early breast cancer.

    HealthTech guidance
    Published
    9 May 2024
    View recommendations

    Sections for HTG719

  11. Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)

    Evidence-based recommendations on andexanet alfa (Ondexxya) for reversing anticoagulation form apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding.

    Technology appraisal guidance
    Last updated
    15 January 2025
    View recommendations

    Sections for TA697

  12. Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]

    Discontinued Reference number: GID-TA10764

    Technology appraisal guidance
    Discontinued

  13. Assessment of disease severity and impact:- In children, young people and adults with psoriasis, can tools be developed and/or existing ones further refined and validated to: - assess disease severity and impact in both non-specialist and specialist healthcare settings, to facilitate assessment, appropriate referral, treatment planning and measurement of outcomes - measure burden and cumulative effect of disease activity, severity and impact for people with both psoriasis and psoriatic arthritis?

    disease severity and impact is fundamental to delivering high-quality health care and measuring outcomes. The evidence review indicates...

    Research recommendation
    Published
    9 June 2015

  14. Housing: planning to improve health and wellbeing

    Discontinued Reference number: GID-NG10053

    NICE guideline
    Discontinued

  15. What interventions are effective and cost effective at raising awareness of the health risks of damp and mould in the home?

    for vulnerable groups.In the committee's experience, professionals such as care workers and health visitors, and the public, are...

    Research recommendation
    Published
    10 February 2020